Lonza Group consensus and earnings outlook, what analysts see for the shares

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 07:23.

Lonza Group AG (CH0013841017) starts the week with investor attention on its upcoming half-year 2026 results and the broader earnings season for global CDMO peers. The Swiss stock trades on SIX Swiss Exchange in Zurich, where it is part of the blue-chip SMI peer universe alongside major healthcare names.

What recent reports highlight

Lonza last reported its full-year 2025 figures in late January 2026, confirming mid-single-digit sales growth and an EBITDA margin in the mid-to-high twenties, according to company disclosures and subsequent market commentary. Around that time, several analysts updated their models for the contract development and manufacturing group, with a focus on biologics capacity utilization and capital expenditure plans.

In research summaries compiled on financial portals, a majority of covering houses reportedly maintain a Buy or Hold stance on Lonza stock, while only a minority rate it Sell or Underperform. These consensus snapshots typically show a 12-month price target implying moderate upside from recent trading levels, though the dispersion of targets reflects differing views on long-term demand for biologics manufacturing and cell and gene therapy services.

Analyst consensus into the next results

Into the next earnings release, analysts generally expect Lonza to deliver low-to-mid single-digit revenue growth year-on-year in the first half of 2026, with some margin pressure from ongoing investment projects but support from higher volumes in large-scale biologics contracts. Several research notes in recent months have underlined the importance of execution in newly ramped facilities and the timing of customer pipeline decisions for advanced therapies.

For investors comparing Lonza with international peers such as Catalent in the United States or smaller European CDMO operators, the Swiss group is often viewed as a relatively diversified platform across biopharma, nutrition, and specialty ingredients. This diversification is cited in analyst work as a factor that can partially mitigate cyclical swings in individual product categories while still tying the company closely to the broader pharmaceutical and biotech investment cycle.

How Lonza makes its money

Lonza generates most of its revenue by providing contract development and manufacturing services to pharmaceutical and biotechnology companies, especially for biologic drugs such as monoclonal antibodies and other complex molecules. In addition to its biopharma operations, the company also offers specialized ingredients and services in areas like consumer health and nutrition, leveraging its process-engineering expertise across multiple end markets.

Where the stock trades today

Lonza Group shares most recently traded on SIX Swiss Exchange in Zurich at a level around the low triple-digit Swiss franc range per share, according to recent price data from exchange and financial-information providers. This places the company among the larger healthcare-related listings in the Swiss market by market capitalization, though day-to-day share-price movements continue to depend on sector sentiment and company-specific news.